0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global HER2 Targeting ADC Drugs Market Research Report 2026
Published Date: 2026-01-10
|
Report Code: QYRE-Auto-18K20217
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global HER2 Targeting ADC Drugs Market Research Report 2026
BUY CHAPTERS

Global HER2 Targeting ADC Drugs Market Research Report 2026

Code: QYRE-Auto-18K20217
Report
2026-01-10
Pages:109
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

HER2 Targeting ADC Drugs Market Size

The global HER2 Targeting ADC Drugs market was valued at US$ 7984 million in 2025 and is anticipated to reach US$ 14124 million by 2032, at a CAGR of 8.2% from 2026 to 2032.

HER2 Targeting ADC Drugs Market

HER2 Targeting ADC Drugs Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on HER2 Targeting ADC Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
In 2025, global HER2 Targeting ADC Drugs reached approximately 6.99 M Units, with an average global market price of around 1143 USD per Unit.
HER2 Targeting ADC Drugs (HER2-targeted antibody–drug conjugates) are a class of targeted cancer medicines that use an anti-HER2 monoclonal antibody to recognize and bind tumor cells with HER2 overexpression, amplification, or certain HER2-driven biology, and then deliver a highly potent cytotoxic payload into (and sometimes around) those cells. Structurally, they are built from three essential parts: (1) the HER2 antibody (the “homing” component), (2) a chemical linker (designed to be stable in blood but release the payload under specific conditions), and (3) the payload (a cell-killing drug such as a microtubule inhibitor or topoisomerase I inhibitor). After binding HER2, the ADC is typically internalized and processed so the payload can be released to damage critical cellular machinery and trigger cancer cell death; depending on the payload/linker properties, some HER2 ADCs can also produce a bystander effect, meaning the released payload may diffuse to kill nearby tumor cells that have lower HER2 expression.
HER2 Targeting ADC Drugs fuse the validated targeting precision of anti-HER2 antibodies with the tumor-killing power of highly potent payloads, offering a pragmatic way to overcome two persistent oncology pain points at once: the limited durability of benefit from many standard targeted agents once resistance emerges, and the systemic toxicity that often constrains conventional chemotherapy. By using HER2 as a delivery address, these conjugates can concentrate cytotoxic exposure inside cancer cells and—depending on linker and payload design—extend activity into heterogeneous tumors through bystander killing, which is increasingly important as clinicians recognize that clinically meaningful HER2 biology exists beyond the classic “HER2-positive” bucket. Looking forward, the category’s market potential is supported by broad applicability across major solid tumors, steady innovation that improves therapeutic index through smarter linkers, controlled conjugation, and next-generation payloads, and the likelihood that HER2 ADCs will become central “backbone” options that can be sequenced with, or paired alongside, endocrine therapy, immunotherapy, and other targeted agents—positioning the space for sustained expansion without relying on unrealistic expectations.
The core raw materials for HER2 Targeting ADC Drugs mainly include anti-HER2 antibodies, linkers, and auxiliary materials. Typical suppliers include Roche, Daiichi Sankyo, Merck, Thermo Fisher, etc. The downstream applications are mainly in the treatment of diseases such as breast cancer.
The production capacity of HER2 Targeting ADC Drugs varies greatly depending on the antibody production, conjugation process, quality control, and supply chain support. The gross profit margin of HER2 Targeting ADC Drugs is in the range of 70%-80%.
The North American market for HER2 Targeting ADC Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for HER2 Targeting ADC Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of HER2 Targeting ADC Drugs include Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global HER2 Targeting ADC Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HER2 Targeting ADC Drugs. The HER2 Targeting ADC Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global HER2 Targeting ADC Drugs market comprehensively. Regional market sizes by Type, by Application, by HER2 Expression Level, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist HER2 Targeting ADC Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of HER2 Targeting ADC Drugs Market Report

Report Metric Details
Report Name HER2 Targeting ADC Drugs Market
Accounted market size in 2025 US$ 7984 million
Forecasted market size in 2032 US$ 14124 million
CAGR 8.2%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Trastuzumab Type
  • Non-trastuzumab Type
Segment by HER2 Expression Level
  • HER2 Positive
  • HER2 Low Expression
Segment by Antibody
  • Monoclonal Antibody
  • Bispecific Antibody
  • Others
by Application
  • Breast Cancer
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by HER2 Expression Level, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for HER2 Targeting ADC Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines HER2 Targeting ADC Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is HER2 Targeting ADC Drugs Market growing?

Ans: The HER2 Targeting ADC Drugs Market witnessing a CAGR of 8.2% during the forecast period 2026-2032.

What is the HER2 Targeting ADC Drugs Market size in 2032?

Ans: The HER2 Targeting ADC Drugs Market size in 2032 will be US$ 14124 million.

Who are the main players in the HER2 Targeting ADC Drugs Market report?

Ans: The main players in the HER2 Targeting ADC Drugs Market are Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical

What are the Application segmentation covered in the HER2 Targeting ADC Drugs Market report?

Ans: The Applications covered in the HER2 Targeting ADC Drugs Market report are Breast Cancer, Others

What are the Type segmentation covered in the HER2 Targeting ADC Drugs Market report?

Ans: The Types covered in the HER2 Targeting ADC Drugs Market report are Trastuzumab Type, Non-trastuzumab Type

1 HER2 Targeting ADC Drugs Market Overview
1.1 Product Definition
1.2 HER2 Targeting ADC Drugs by Type
1.2.1 Global HER2 Targeting ADC Drugs Market Value by Type: 2025 vs 2032
1.2.2 Trastuzumab Type
1.2.3 Non-trastuzumab Type
1.3 HER2 Targeting ADC Drugs by HER2 Expression Level
1.3.1 Global HER2 Targeting ADC Drugs Market Value by HER2 Expression Level: 2025 vs 2032
1.3.2 HER2 Positive
1.3.3 HER2 Low Expression
1.4 HER2 Targeting ADC Drugs by Antibody
1.4.1 Global HER2 Targeting ADC Drugs Market Value by Antibody: 2025 vs 2032
1.4.2 Monoclonal Antibody
1.4.3 Bispecific Antibody
1.4.4 Others
1.5 HER2 Targeting ADC Drugs by Application
1.5.1 Global HER2 Targeting ADC Drugs Market Value by Application: 2025 vs 2032
1.5.2 Breast Cancer
1.5.3 Others
1.6 Global HER2 Targeting ADC Drugs Market Size Estimates and Forecasts
1.6.1 Global HER2 Targeting ADC Drugs Revenue 2021–2032
1.6.2 Global HER2 Targeting ADC Drugs Sales 2021–2032
1.6.3 Global HER2 Targeting ADC Drugs Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 HER2 Targeting ADC Drugs Market Competition by Manufacturers
2.1 Global HER2 Targeting ADC Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global HER2 Targeting ADC Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global HER2 Targeting ADC Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of HER2 Targeting ADC Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of HER2 Targeting ADC Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of HER2 Targeting ADC Drugs, Product Types and Applications
2.7 Global Key Manufacturers of HER2 Targeting ADC Drugs, Date of Entry into the Industry
2.8 Global HER2 Targeting ADC Drugs Market Competitive Situation and Trends
2.8.1 Global HER2 Targeting ADC Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global HER2 Targeting ADC Drugs Players Market Share by Revenue
2.8.3 Global HER2 Targeting ADC Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HER2 Targeting ADC Drugs Market Scenario by Region
3.1 Global HER2 Targeting ADC Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global HER2 Targeting ADC Drugs Sales by Region: 2021–2032
3.2.1 Global HER2 Targeting ADC Drugs Sales by Region: 2021–2026
3.2.2 Global HER2 Targeting ADC Drugs Sales by Region: 2027–2032
3.3 Global HER2 Targeting ADC Drugs Revenue by Region: 2021–2032
3.3.1 Global HER2 Targeting ADC Drugs Revenue by Region: 2021–2026
3.3.2 Global HER2 Targeting ADC Drugs Revenue by Region: 2027–2032
3.4 North America HER2 Targeting ADC Drugs Market Facts & Figures by Country
3.4.1 North America HER2 Targeting ADC Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America HER2 Targeting ADC Drugs Sales by Country (2021–2032)
3.4.3 North America HER2 Targeting ADC Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe HER2 Targeting ADC Drugs Market Facts & Figures by Country
3.5.1 Europe HER2 Targeting ADC Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe HER2 Targeting ADC Drugs Sales by Country (2021–2032)
3.5.3 Europe HER2 Targeting ADC Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HER2 Targeting ADC Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific HER2 Targeting ADC Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific HER2 Targeting ADC Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific HER2 Targeting ADC Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HER2 Targeting ADC Drugs Market Facts & Figures by Country
3.7.1 Latin America HER2 Targeting ADC Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America HER2 Targeting ADC Drugs Sales by Country (2021–2032)
3.7.3 Latin America HER2 Targeting ADC Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HER2 Targeting ADC Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa HER2 Targeting ADC Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa HER2 Targeting ADC Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa HER2 Targeting ADC Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HER2 Targeting ADC Drugs Sales by Type (2021–2032)
4.1.1 Global HER2 Targeting ADC Drugs Sales by Type (2021–2026)
4.1.2 Global HER2 Targeting ADC Drugs Sales by Type (2027–2032)
4.1.3 Global HER2 Targeting ADC Drugs Sales Market Share by Type (2021–2032)
4.2 Global HER2 Targeting ADC Drugs Revenue by Type (2021–2032)
4.2.1 Global HER2 Targeting ADC Drugs Revenue by Type (2021–2026)
4.2.2 Global HER2 Targeting ADC Drugs Revenue by Type (2027–2032)
4.2.3 Global HER2 Targeting ADC Drugs Revenue Market Share by Type (2021–2032)
4.3 Global HER2 Targeting ADC Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global HER2 Targeting ADC Drugs Sales by Application (2021–2032)
5.1.1 Global HER2 Targeting ADC Drugs Sales by Application (2021–2026)
5.1.2 Global HER2 Targeting ADC Drugs Sales by Application (2027–2032)
5.1.3 Global HER2 Targeting ADC Drugs Sales Market Share by Application (2021–2032)
5.2 Global HER2 Targeting ADC Drugs Revenue by Application (2021–2032)
5.2.1 Global HER2 Targeting ADC Drugs Revenue by Application (2021–2026)
5.2.2 Global HER2 Targeting ADC Drugs Revenue by Application (2027–2032)
5.2.3 Global HER2 Targeting ADC Drugs Revenue Market Share by Application (2021–2032)
5.3 Global HER2 Targeting ADC Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche HER2 Targeting ADC Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche HER2 Targeting ADC Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca HER2 Targeting ADC Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 AstraZeneca HER2 Targeting ADC Drugs Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Daiichi Sankyo
6.3.1 Daiichi Sankyo Company Information
6.3.2 Daiichi Sankyo Description and Business Overview
6.3.3 Daiichi Sankyo HER2 Targeting ADC Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Daiichi Sankyo HER2 Targeting ADC Drugs Product Portfolio
6.3.5 Daiichi Sankyo Recent Developments/Updates
6.4 Remegen
6.4.1 Remegen Company Information
6.4.2 Remegen Description and Business Overview
6.4.3 Remegen HER2 Targeting ADC Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Remegen HER2 Targeting ADC Drugs Product Portfolio
6.4.5 Remegen Recent Developments/Updates
6.5 Jiangsu Hengrui Medicine
6.5.1 Jiangsu Hengrui Medicine Company Information
6.5.2 Jiangsu Hengrui Medicine Description and Business Overview
6.5.3 Jiangsu Hengrui Medicine HER2 Targeting ADC Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Jiangsu Hengrui Medicine HER2 Targeting ADC Drugs Product Portfolio
6.5.5 Jiangsu Hengrui Medicine Recent Developments/Updates
6.6 Shanghai Henlius Biotech
6.6.1 Shanghai Henlius Biotech Company Information
6.6.2 Shanghai Henlius Biotech Description and Business Overview
6.6.3 Shanghai Henlius Biotech HER2 Targeting ADC Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Shanghai Henlius Biotech HER2 Targeting ADC Drugs Product Portfolio
6.6.5 Shanghai Henlius Biotech Recent Developments/Updates
6.7 Sichuan Kelun-Biotech Biopharmaceutical
6.7.1 Sichuan Kelun-Biotech Biopharmaceutical Company Information
6.7.2 Sichuan Kelun-Biotech Biopharmaceutical Description and Business Overview
6.7.3 Sichuan Kelun-Biotech Biopharmaceutical HER2 Targeting ADC Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Sichuan Kelun-Biotech Biopharmaceutical HER2 Targeting ADC Drugs Product Portfolio
6.7.5 Sichuan Kelun-Biotech Biopharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HER2 Targeting ADC Drugs Industry Chain Analysis
7.2 HER2 Targeting ADC Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HER2 Targeting ADC Drugs Production Mode & Process Analysis
7.4 HER2 Targeting ADC Drugs Sales and Marketing
7.4.1 HER2 Targeting ADC Drugs Sales Channels
7.4.2 HER2 Targeting ADC Drugs Distributors
7.5 HER2 Targeting ADC Drugs Customer Analysis
8 HER2 Targeting ADC Drugs Market Dynamics
8.1 HER2 Targeting ADC Drugs Industry Trends
8.2 HER2 Targeting ADC Drugs Market Drivers
8.3 HER2 Targeting ADC Drugs Market Challenges
8.4 HER2 Targeting ADC Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global HER2 Targeting ADC Drugs Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global HER2 Targeting ADC Drugs Market Value by HER2 Expression Level (US$ Million), 2025 vs 2032
 Table 3. Global HER2 Targeting ADC Drugs Market Value by Antibody (US$ Million), 2025 vs 2032
 Table 4. Global HER2 Targeting ADC Drugs Market Value by Application (US$ Million), 2025 vs 2032
 Table 5. Global HER2 Targeting ADC Drugs Market Competitive Situation by Manufacturers in 2025
 Table 6. Global HER2 Targeting ADC Drugs Sales (K Units) of Key Manufacturers (2021–2026)
 Table 7. Global HER2 Targeting ADC Drugs Sales Market Share by Manufacturers (2021–2026)
 Table 8. Global HER2 Targeting ADC Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 9. Global HER2 Targeting ADC Drugs Revenue Share by Manufacturers (2021–2026)
 Table 10. Global Market HER2 Targeting ADC Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 11. Global Key Players of HER2 Targeting ADC Drugs, Industry Ranking, 2023 vs 2024 vs 2025
 Table 12. Global Key Manufacturers of HER2 Targeting ADC Drugs, Manufacturing Sites and Headquarters
 Table 13. Global Key Manufacturers of HER2 Targeting ADC Drugs, Product Types and Applications
 Table 14. Global Key Manufacturers of HER2 Targeting ADC Drugs, Date of Entry into the Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global HER2 Targeting ADC Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on HER2 Targeting ADC Drugs Revenue, 2025
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global HER2 Targeting ADC Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 19. Global HER2 Targeting ADC Drugs Sales by Region (K Units), 2021–2026
 Table 20. Global HER2 Targeting ADC Drugs Sales Market Share by Region (2021–2026)
 Table 21. Global HER2 Targeting ADC Drugs Sales by Region (K Units), 2027–2032
 Table 22. Global HER2 Targeting ADC Drugs Sales Market Share by Region (2027–2032)
 Table 23. Global HER2 Targeting ADC Drugs Revenue by Region (US$ Million), 2021–2026
 Table 24. Global HER2 Targeting ADC Drugs Revenue Market Share by Region (2021–2026)
 Table 25. Global HER2 Targeting ADC Drugs Revenue by Region (US$ Million), 2027–2032
 Table 26. Global HER2 Targeting ADC Drugs Revenue Market Share by Region (2027–2032)
 Table 27. North America HER2 Targeting ADC Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 28. North America HER2 Targeting ADC Drugs Sales by Country (K Units), 2021–2026
 Table 29. North America HER2 Targeting ADC Drugs Sales by Country (K Units), 2027–2032
 Table 30. North America HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2021–2026
 Table 31. North America HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2027–2032
 Table 32. Europe HER2 Targeting ADC Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 33. Europe HER2 Targeting ADC Drugs Sales by Country (K Units), 2021–2026
 Table 34. Europe HER2 Targeting ADC Drugs Sales by Country (K Units), 2027–2032
 Table 35. Europe HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2021–2026
 Table 36. Europe HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2027–2032
 Table 37. Asia Pacific HER2 Targeting ADC Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 38. Asia Pacific HER2 Targeting ADC Drugs Sales by Region (K Units), 2021–2026
 Table 39. Asia Pacific HER2 Targeting ADC Drugs Sales by Region (K Units), 2027–2032
 Table 40. Asia Pacific HER2 Targeting ADC Drugs Revenue by Region (US$ Million), 2021–2026
 Table 41. Asia Pacific HER2 Targeting ADC Drugs Revenue by Region (US$ Million), 2027–2032
 Table 42. Latin America HER2 Targeting ADC Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 43. Latin America HER2 Targeting ADC Drugs Sales by Country (K Units), 2021–2026
 Table 44. Latin America HER2 Targeting ADC Drugs Sales by Country (K Units), 2027–2032
 Table 45. Latin America HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2021–2026
 Table 46. Latin America HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2027–2032
 Table 47. Middle East and Africa HER2 Targeting ADC Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 48. Middle East and Africa HER2 Targeting ADC Drugs Sales by Country (K Units), 2021–2026
 Table 49. Middle East and Africa HER2 Targeting ADC Drugs Sales by Country (K Units), 2027–2032
 Table 50. Middle East and Africa HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2021–2026
 Table 51. Middle East and Africa HER2 Targeting ADC Drugs Revenue by Country (US$ Million), 2027–2032
 Table 52. Global HER2 Targeting ADC Drugs Sales (K Units) by Type (2021–2026)
 Table 53. Global HER2 Targeting ADC Drugs Sales (K Units) by Type (2027–2032)
 Table 54. Global HER2 Targeting ADC Drugs Sales Market Share by Type (2021–2026)
 Table 55. Global HER2 Targeting ADC Drugs Sales Market Share by Type (2027–2032)
 Table 56. Global HER2 Targeting ADC Drugs Revenue (US$ Million) by Type (2021–2026)
 Table 57. Global HER2 Targeting ADC Drugs Revenue (US$ Million) by Type (2027–2032)
 Table 58. Global HER2 Targeting ADC Drugs Revenue Market Share by Type (2021–2026)
 Table 59. Global HER2 Targeting ADC Drugs Revenue Market Share by Type (2027–2032)
 Table 60. Global HER2 Targeting ADC Drugs Price (US$/Unit) by Type (2021–2026)
 Table 61. Global HER2 Targeting ADC Drugs Price (US$/Unit) by Type (2027–2032)
 Table 62. Global HER2 Targeting ADC Drugs Sales (K Units) by Application (2021–2026)
 Table 63. Global HER2 Targeting ADC Drugs Sales (K Units) by Application (2027–2032)
 Table 64. Global HER2 Targeting ADC Drugs Sales Market Share by Application (2021–2026)
 Table 65. Global HER2 Targeting ADC Drugs Sales Market Share by Application (2027–2032)
 Table 66. Global HER2 Targeting ADC Drugs Revenue (US$ Million) by Application (2021–2026)
 Table 67. Global HER2 Targeting ADC Drugs Revenue (US$ Million) by Application (2027–2032)
 Table 68. Global HER2 Targeting ADC Drugs Revenue Market Share by Application (2021–2026)
 Table 69. Global HER2 Targeting ADC Drugs Revenue Market Share by Application (2027–2032)
 Table 70. Global HER2 Targeting ADC Drugs Price (US$/Unit) by Application (2021–2026)
 Table 71. Global HER2 Targeting ADC Drugs Price (US$/Unit) by Application (2027–2032)
 Table 72. Roche Company Information
 Table 73. Roche Description and Business Overview
 Table 74. Roche HER2 Targeting ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 75. Roche HER2 Targeting ADC Drugs Product
 Table 76. Roche Recent Developments/Updates
 Table 77. AstraZeneca Company Information
 Table 78. AstraZeneca Description and Business Overview
 Table 79. AstraZeneca HER2 Targeting ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 80. AstraZeneca HER2 Targeting ADC Drugs Product
 Table 81. AstraZeneca Recent Developments/Updates
 Table 82. Daiichi Sankyo Company Information
 Table 83. Daiichi Sankyo Description and Business Overview
 Table 84. Daiichi Sankyo HER2 Targeting ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 85. Daiichi Sankyo HER2 Targeting ADC Drugs Product
 Table 86. Daiichi Sankyo Recent Developments/Updates
 Table 87. Remegen Company Information
 Table 88. Remegen Description and Business Overview
 Table 89. Remegen HER2 Targeting ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 90. Remegen HER2 Targeting ADC Drugs Product
 Table 91. Remegen Recent Developments/Updates
 Table 92. Jiangsu Hengrui Medicine Company Information
 Table 93. Jiangsu Hengrui Medicine Description and Business Overview
 Table 94. Jiangsu Hengrui Medicine HER2 Targeting ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 95. Jiangsu Hengrui Medicine HER2 Targeting ADC Drugs Product
 Table 96. Jiangsu Hengrui Medicine Recent Developments/Updates
 Table 97. Shanghai Henlius Biotech Company Information
 Table 98. Shanghai Henlius Biotech Description and Business Overview
 Table 99. Shanghai Henlius Biotech HER2 Targeting ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 100. Shanghai Henlius Biotech HER2 Targeting ADC Drugs Product
 Table 101. Shanghai Henlius Biotech Recent Developments/Updates
 Table 102. Sichuan Kelun-Biotech Biopharmaceutical Company Information
 Table 103. Sichuan Kelun-Biotech Biopharmaceutical Description and Business Overview
 Table 104. Sichuan Kelun-Biotech Biopharmaceutical HER2 Targeting ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 105. Sichuan Kelun-Biotech Biopharmaceutical HER2 Targeting ADC Drugs Product
 Table 106. Sichuan Kelun-Biotech Biopharmaceutical Recent Developments/Updates
 Table 107. Key Raw Materials Lists
 Table 108. Raw Materials Key Suppliers Lists
 Table 109. HER2 Targeting ADC Drugs Distributors List
 Table 110. HER2 Targeting ADC Drugs Customers List
 Table 111. HER2 Targeting ADC Drugs Market Trends
 Table 112. HER2 Targeting ADC Drugs Market Drivers
 Table 113. HER2 Targeting ADC Drugs Market Challenges
 Table 114. HER2 Targeting ADC Drugs Market Restraints
 Table 115. Research Programs/Design for This Report
 Table 116. Key Data Information from Secondary Sources
 Table 117. Key Data Information from Primary Sources
 Table 118. Authors List of This Report


List of Figures
 Figure 1. Product Picture of HER2 Targeting ADC Drugs
 Figure 2. Global HER2 Targeting ADC Drugs Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global HER2 Targeting ADC Drugs Market Share by Type: 2025 & 2032
 Figure 4. Trastuzumab Type Product Picture
 Figure 5. Non-trastuzumab Type Product Picture
 Figure 6. Global HER2 Targeting ADC Drugs Market Value by HER2 Expression Level (US$ Million), 2021–2032
 Figure 7. Global HER2 Targeting ADC Drugs Market Share by HER2 Expression Level: 2025 vs 2032
 Figure 8. HER2 Positive Product Picture
 Figure 9. HER2 Low Expression Product Picture
 Figure 10. Global HER2 Targeting ADC Drugs Market Value by Antibody (US$ Million), 2021–2032
 Figure 11. Global HER2 Targeting ADC Drugs Market Share by Antibody: 2025 vs 2032
 Figure 12. Monoclonal Antibody Product Picture
 Figure 13. Bispecific Antibody Product Picture
 Figure 14. Others Product Picture
 Figure 15. Global HER2 Targeting ADC Drugs Market Value by Application (US$ Million), 2021–2032
 Figure 16. Global HER2 Targeting ADC Drugs Market Share by Application: 2025 & 2032
 Figure 17. Breast Cancer
 Figure 18. Others
 Figure 19. Global HER2 Targeting ADC Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 20. Global HER2 Targeting ADC Drugs Market Size (US$ Million), 2021–2032
 Figure 21. Global HER2 Targeting ADC Drugs Sales (K Units), 2021–2032
 Figure 22. Global HER2 Targeting ADC Drugs Average Price (US$/Unit), 2021–2032
 Figure 23. HER2 Targeting ADC Drugs Report Years Considered
 Figure 24. HER2 Targeting ADC Drugs Sales Share by Manufacturers in 2025
 Figure 25. Global HER2 Targeting ADC Drugs Revenue Share by Manufacturers in 2025
 Figure 26. Top 5 and Top 10 Global HER2 Targeting ADC Drugs Players: Market Share by Revenue in HER2 Targeting ADC Drugs in 2025
 Figure 27. HER2 Targeting ADC Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 28. Global HER2 Targeting ADC Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 29. North America HER2 Targeting ADC Drugs Sales Market Share by Country (2021–2032)
 Figure 30. North America HER2 Targeting ADC Drugs Revenue Market Share by Country (2021–2032)
 Figure 31. United States HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Canada HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Europe HER2 Targeting ADC Drugs Sales Market Share by Country (2021–2032)
 Figure 34. Europe HER2 Targeting ADC Drugs Revenue Market Share by Country (2021–2032)
 Figure 35. Germany HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. France HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. U.K. HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Italy HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Russia HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Asia Pacific HER2 Targeting ADC Drugs Sales Market Share by Region (2021–2032)
 Figure 41. Asia Pacific HER2 Targeting ADC Drugs Revenue Market Share by Region (2021–2032)
 Figure 42. China HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Japan HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. South Korea HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. India HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Australia HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. China Taiwan HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Southeast Asia HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Latin America HER2 Targeting ADC Drugs Sales Market Share by Country (2021–2032)
 Figure 50. Latin America HER2 Targeting ADC Drugs Revenue Market Share by Country (2021–2032)
 Figure 51. Mexico HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Brazil HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Argentina HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Colombia HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Middle East and Africa HER2 Targeting ADC Drugs Sales Market Share by Country (2021–2032)
 Figure 56. Middle East and Africa HER2 Targeting ADC Drugs Revenue Market Share by Country (2021–2032)
 Figure 57. Turkey HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 58. Saudi Arabia HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 59. UAE HER2 Targeting ADC Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 60. Global Sales Market Share of HER2 Targeting ADC Drugs by Type (2021–2032)
 Figure 61. Global Revenue Market Share of HER2 Targeting ADC Drugs by Type (2021–2032)
 Figure 62. Global HER2 Targeting ADC Drugs Price (US$/Unit) by Type (2021–2032)
 Figure 63. Global Sales Market Share of HER2 Targeting ADC Drugs by Application (2021–2032)
 Figure 64. Global Revenue Market Share of HER2 Targeting ADC Drugs by Application (2021–2032)
 Figure 65. Global HER2 Targeting ADC Drugs Price (US$/Unit) by Application (2021–2032)
 Figure 66. HER2 Targeting ADC Drugs Value Chain
 Figure 67. Channels of Distribution (Direct Vs Distribution)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS